Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
Nogami K, Taki M, Matsushita T, Kojima T, Oka T, Ohga S, Kawakami K, Sakai M, Suzuki T, Higasa S, Horikoshi Y, Shinozawa K, Tamura S, Yada K, Imaizumi M, Ohtsuka Y, Iwasaki F, Kobayashi M, Takamatsu J, Takedani H, Nakadate H, Matsuo Y, Matsumoto T, Fujii T, Fukutake K, Shirahata A, Yoshioka A, Shima M; J-HIS2 study group. Nogami K, et al. Among authors: taki m. Haemophilia. 2022 Sep;28(5):745-759. doi: 10.1111/hae.14602. Epub 2022 Jun 11. Haemophilia. 2022. PMID: 35689832
An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A; STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS. Shirahata A, et al. Among authors: taki m. Haemophilia. 2011 Sep;17(5):771-6. doi: 10.1111/j.1365-2516.2011.02599.x. Epub 2011 Jun 20. Haemophilia. 2011. PMID: 21682824
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. Shinkoda Y, et al. Among authors: taki m. Haemophilia. 2017 Jan;23(1):59-66. doi: 10.1111/hae.13050. Epub 2016 Aug 1. Haemophilia. 2017. PMID: 27480904 Clinical Trial.
Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.
Fukutake K, Taki M, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Uchikawa H, Takagi H, Arai M, Engl W, Shirahata A. Fukutake K, et al. Among authors: taki m. Int J Hematol. 2019 Mar;109(3):336-345. doi: 10.1007/s12185-018-02574-x. Epub 2019 Jan 2. Int J Hematol. 2019. PMID: 30604312 Clinical Trial.
Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
Shinozawa K, Yada K, Kojima T, Nogami K, Taki M, Fukutake K, Yoshioka A, Shirahata A, Shima M; study group on JAPAN HEMOPHILIA INHIBITOR STUDY (J-HIS). Shinozawa K, et al. Among authors: taki m. Thromb Haemost. 2021 May;121(5):603-615. doi: 10.1055/s-0040-1721385. Epub 2020 Nov 30. Thromb Haemost. 2021. PMID: 33254277
618 results